



PE
8/21/02

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549


Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For 21 August, 2002

GlaxoSmithKline plc
(Name of registrant)

GLAXOSMITHKLINE, 980 GREAT WEST ROAD,
BRENTFORD, MIDDLESEX TW8 9GS
(Address of principal executive offices)



PROCESSED

AUG 29 2002

**THOMSON
FINANCIAL**

Indicated by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F

Form 20-F ____ Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes ____ No ____



GlaxoSmithKline

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

Tel. +44 (0)20 8047 5000

www.gsk.com

Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

16 August 2002

The Administrators of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") notified GlaxoSmithKline plc on the 20 August 2002, that as a result of movement in the fund on the 16 August 2002, the number of Ordinary Share ADRs held by the fund had increased from 18,011,073 to 18,066,689 at an average price of \$40.88.

The Trust is a discretionary fund of which all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two of the Company's directors, Dr J P Garnier and Mr J D Coombe are therefore interested in the shares held in the fund from time to time in the same way as other employees or former employees of GlaxoSmithKline plc and its subsidiaries.

S M Bicknell
Company Secretary

20 August 2002

Registered in England & Wales
No. 3888792

Registered office
980 Great West Road


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: 20 August, 2002

By:



VICTORIA LLEWELLYN
Authorised Signatory for and on
behalf of GlaxoSmithKline plc